Literature DB >> 11579677

High prevalence of RET tyrosine kinase activation in Mexican patients with papillary thyroid carcinomas.

I Martínez1, A Mantilla, M E Medrano, R Hernández, D M Hernández, M Lazos, H Santiago, B González, A Hidalgo, M Salcedo.   

Abstract

RET/PTC oncogene expression is restricted to papillary thyroid carcinomas (PTC). At least three forms of this oncogene have been described. These are generated by the rearrangement of the 5'-terminal region of different expressed genes with the tyrosine-kinase (TK) domain of the ret proto-oncogene. Several studies showing the correlation between the expression of this oncogene, clinical outcome, and histological subtypes have been published. Thirty-five paraffin-embedded PTC samples from patients without a history of radiation exposure were studied. Immunohistochemistry (IHC) and in situ hybridization (ISH) were used to determine a possible correlation between RET activation, clinical outcome, and tumor subtype. Almost half of the studied cases presented with tumoral extension or metastases. Ret gene transcripts and protein were found in all PTC variants as well as in their corresponding metastases. In contrast, none of the follicular adenomas, goiters, or normal follicular cells from the thyroid gland showed evidence of ret activation. We observed a high frequency of ret expression in PTCs, suggesting that ret activation is a common event in nonradiation-related PTC from Mexican patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579677     DOI: 10.1385/ep:12:2:113

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  39 in total

1.  Prevalence, significance, and biological behavior of ret/PTC1 associated papillary thyroid carcinoma.

Authors:  F Cetta
Journal:  J Clin Endocrinol Metab       Date:  1997-05       Impact factor: 5.958

2.  Thyroid tumor pathology. Proceedings of an international workshop. San Miniato, Italy, October 1984.

Authors: 
Journal:  Semin Diagn Pathol       Date:  1985-05       Impact factor: 3.464

3.  Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

Authors:  M Santoro; F Carlomagno; I D Hay; M A Herrmann; M Grieco; R Melillo; M A Pierotti; I Bongarzone; G Della Porta; N Berger
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

4.  Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method.

Authors:  Y Ishizaka; S Kobayashi; T Ushijima; S Hirohashi; T Sugimura; M Nagao
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

5.  Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5.

Authors:  S Klugbauer; E P Demidchik; E Lengfelder; H M Rabes
Journal:  Cancer Res       Date:  1998-01-15       Impact factor: 12.701

6.  Detection of the PTC/retTPC oncogene in human thyroid cancers.

Authors:  S M Jhiang; D R Caruso; E Gilmore; Y Ishizaka; T Tahira; M Nagao; I M Chiu; E L Mazzaferri
Journal:  Oncogene       Date:  1992-07       Impact factor: 9.867

7.  Development of a single-step duplex RT-PCR detecting different forms of ret activation, and identification of the third form of in vivo ret activation in human papillary thyroid carcinoma.

Authors:  S M Jhiang; P A Smanik; E L Mazzaferri
Journal:  Cancer Lett       Date:  1994-04-01       Impact factor: 8.679

8.  High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident.

Authors:  S Klugbauer; E Lengfelder; E P Demidchik; H M Rabes
Journal:  Oncogene       Date:  1995-12-21       Impact factor: 9.867

9.  A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases.

Authors:  A Fusco; M Grieco; M Santoro; M T Berlingieri; S Pilotti; M A Pierotti; G Della Porta; G Vecchio
Journal:  Nature       Date:  1987 Jul 9-15       Impact factor: 49.962

10.  Detection of RET oncogene activation in human papillary thyroid carcinomas by in situ hybridisation.

Authors:  N Fabien; C Paulin; M Santoro; N Berger; M Grieco; D Galvain; Y Barbier; P M Dubois; A Fusco
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.